TXMD TherapeuticsMD Inc.
TherapeuticsMD, Inc. is a pharmaceutical company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
Company profile
Ticker
TXMD
Exchange
Website
CEO
Robert G. Finizio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMHN, Inc., CROFF ENTERPRISES INC, CROFF OIL CO
SEC CIK
Corporate docs
IRS number
870233535
TXMD stock data
()
Investment data
Securities sold
Number of investors
Calendar
7 Aug 20
19 Sep 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 18 Jun 20 | James DArecca | RSU Common Stock | Grant | Aquire A | No | 0 | 651,500 | 0 | 651,500 |
| 18 Jun 20 | James DArecca | Performance Stock Units Common Stock | Grant | Aquire A | No | 0 | 151,500 | 0 | 151,500 |
| 18 Jun 20 | Musing Jules A. | RSU Common Stock | Grant | Aquire A | No | 0 | 96,864 | 0 | 96,864 |
| 18 Jun 20 | Ling Karen | RSU Common Stock | Grant | Aquire A | No | 0 | 96,864 | 0 | 96,864 |
Institutional ownership Q2 2020
55.7% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 148 |
| Opened positions | 27 |
| Closed positions | 21 |
| Increased positions | 45 |
| Reduced positions | 36 |
13F shares |
Current |
|---|---|
| Total value | 214.02M |
| Total shares | 151.69M |
| Total puts | 720.3K |
| Total calls | 395.4K |
| Total put/call ratio | 1.8 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK BlackRock | 21.26M | $26.58M |
| N Price T Rowe Associates | 19.17M | $23.97M |
| FMR | 14.92M | $18.65M |
| JPM JPMorgan Chase & Co. | 13.07M | $16.34M |
| Vanguard | 12.57M | $15.71M |
| Rubric Capital Management | 9.29M | $11.61M |
| C WorldWide Group Holding A/S | 6.19M | $7.74M |
| GMT Capital | 5.99M | $7.48M |
| AMP Ameriprise Financial | 4.63M | $5.78M |
| STT State Street | 4.56M | $5.71M |
Financial report summary
?Competition
Mylan • Pfizer • AMAG Pharmaceuticals • Allergan • Agile Therapeutics • VMS • Allergan • Mylan • Amneal Pharmaceuticals • Amneal Pharmaceuticals
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Abbreviated, absent, accredited, agency, AIG, alleging, Amneal, ANDA, answer, Appendix, attached, BJIUVA, Book, chaired, combat, complaint, Composite, copy, counterclaim, Court, covenant, decile, District, Donegan, EBITDA, enjoining, entirety, equitable, ESPP, exceeded, exemption, exporting, faith, forward, Hong, incorporated, Incorporation, indemnify, induce, infringed, infringement, infringing, invalid, investor, issuable, Jersey, Karen, Kong, lesser, letter, lieu, Ling, live, maintenance, mcg, Michael, monitoring, moving, obsolescence, Orange, outreach, person, pharmacological, pick, pledged, prioritize, prioritizing, progressed, prohibited, promulgated, proxy, purport, put, quarantine, refocused, Restated, saving, Schedule, speaker, Teva, text, thereof, therewith, undrawn, unenforceable, USA, version, Vice, voluntarily
Removed:
broadly, call, deploying, discovery, exclude, fully, monthly, outsourced, PI
Financial reports
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
24 Feb 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
30 Jul 18
Current reports
8-K
Regulation FD Disclosure
14 Sep 20
8-K
TherapeuticsMD® Announces Second Quarter 2020 Financial Results
6 Aug 20
8-K
Regulation FD Disclosure
23 Jun 20
8-K
Departure of Directors or Certain Officers
18 Jun 20
8-K
Departure of Directors or Certain Officers
1 Jun 20
8-K
Termination of a Material Definitive Agreement
15 May 20
8-K
Regulation FD Disclosure
13 May 20
8-K
TherapeuticsMD Announces First Quarter 2020 Financial Results
6 May 20
8-K
Entry into a Material Definitive Agreement
1 May 20
8-K
Departure of Directors or Certain Officers
22 Apr 20
Registration and prospectus
D
$7.5M in options / securities to be acquired, sold $7.5M, 3 investors
14 Aug 20
S-8
Registration of securities for employees
7 Aug 20
POS AM
Prospectus update (post-effective amendment)
24 Feb 20
424B2
Prospectus for primary offering
25 Oct 19
FWP
Free writing prospectus
24 Oct 19
FWP
Free writing prospectus
23 Oct 19
424B5
Prospectus supplement for primary offering
23 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Jun 19
S-8
Registration of securities for employees
21 Jun 19
424B2
Prospectus for primary offering
2 Aug 18
Proxies
DEFA14A
Additional proxy soliciting materials
4 May 20
DEF 14A
Definitive proxy
4 May 20
PRER14A
Preliminary revised proxy
22 Apr 20
PRE 14A
Preliminary proxy
13 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEFA14A
Additional proxy soliciting materials
25 Apr 17
DEF 14A
Definitive proxy
25 Apr 17
Other
EFFECT
Notice of effectiveness
6 May 20
CT ORDER
Confidential treatment order
10 Apr 19
CT ORDER
Confidential treatment order
12 Dec 18
CT ORDER
Confidential treatment order
21 Aug 18
UPLOAD
Letter from SEC
6 Feb 17
CORRESP
Correspondence with SEC
31 Jan 17
UPLOAD
Letter from SEC
25 Jan 17
CORRESP
Correspondence with SEC
29 Dec 16
UPLOAD
Letter from SEC
15 Dec 16
EFFECT
Notice of effectiveness
17 Nov 15
Ownership
4/A
TherapeuticsMD / James DArecca ownership change
8 Aug 20
3
TherapeuticsMD / EDWARD BORKOWSKI ownership change
8 Aug 20
3
TherapeuticsMD / Marlan D Walker ownership change
8 Aug 20
4
TherapeuticsMD / PAUL BISARO ownership change
19 Jun 20
4
TherapeuticsMD / Tommy G Thompson ownership change
19 Jun 20
4
TherapeuticsMD / Angus C. Russell ownership change
19 Jun 20
4
TherapeuticsMD / Gail K Naughton ownership change
19 Jun 20
4
TherapeuticsMD / JULES A. MUSING ownership change
19 Jun 20
4
TherapeuticsMD / Karen Ling ownership change
19 Jun 20
4
TherapeuticsMD / Cooper C. Collins ownership change
19 Jun 20
Patents
APP
Utility
Soluble Estradiol Capsule for Vaginal Insertion
17 Sep 20
According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided.
APP
Utility
Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods
10 Sep 20
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided.
APP
Utility
Natural Combination Hormone Replacement Formulations and Therapies
10 Sep 20
Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided.
APP
Utility
Natural Combination Hormone Replacement Formulations and Therapies
10 Sep 20
Estrogen and progesterone replacement therapies are provided herein.
APP
Utility
Natural Combination Hormone Replacement Formulations and Therapies
10 Sep 20
Estrogen and progesterone replacement therapies are provided herein.